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Classification by Type of Ventricular Arrhythmia Predicts Frequency
of Adverse Cardiac Events From Flecainide
JOEL MORGANROTH, MD, FACC ,* JEFFREY L. ANDERSON, MD, FACC,t
GARY D. GENTZKOW, MOt
Philadelphia. Pennsylvania. Salt Lake City. Utah and St. Paul. Minnesota
Antiarrhythmic therapy is known to be associated with
a significant risk of adverse cardiac reactions, including
a proarrhythmic response. This study assessed in 1,330
patients followed up for 292 ± 393 days the predictive
value for cardiovascular safety of a system by which
patients were classifiedaccording to ventricular arrhyth-
mias on entry, presence or absence of organic heart
disease and drug dose for flecainide acetate. Baseline
arrhythmia subgroups included patients with 1) pre-
mature ventricular complexesonly, 2) nonsustained ven-
tricular tachycardia, and 3) sustained ventricular tachy-
cardia.
Proarrhythmic events occurred in 6.8% of patients
overall and were serious in 2.3% and lethal in 1.0%.
However, proarrhythmia was highly dependent on ar-
rhythmia class on entry: serious nonlethal proar-
rhythmic events occurred in 6.6 % of patients with sus-
tained ventricular tachycardia, only 0.9 % with
nonsustained ventricular tachycardia and 0% with pre-
mature ventricular complexes (p < 0.01). Proar-
rhythmic death occurred in 3. I % of patients with sus-
tained ventricular tachycardia, 0.2% with nonsustained
ventricular tachycardia and 0% with premature ven-
tricular complexes only (p < 0.01). Proarrhythmia was
also influenced by the presence of structural heart dis-
Over the past few years, intense study of new antiarrh ythmic
agents has shown that this class of drugs has the potential
for life-threatening side effects (I ). A reassessment of the
risk/benefit ratio of using antiarrhythmic agents is thus nec-
essary. The physician now must not only consider the
electrocardiographic diagnosis of the ventricular arrhythmia
type in assessing this risk/benefit relation. but also must
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ease: serious nonlethal proarrhythmia occurred in 2.6%
of patients with versus 0.4% of those without organic
heart disease, and death occurred in 1.2 versus 0%,
respectively. These adverse events were also dependent
on dosing regimen. Flecainide caused premature dis-
continuation due to new or worsened heart failure in
1.4% of patients, all with underlying organic heart dis-
ease; however, heart failure was not clearly related to
dose or type of arrhythmia. Symptomatic conduction
disturbances occurred in 2.2%, and were predicted by
preexistent sinus node disease but not by other baseline
features.
The safety of flecainide was markedly enhanced by a
slow, incremental approach to dosing, especially in high
risk patients. Becausemost proarrhythmia occurred early
during dose finding, hospitalization for drug initiation
would appear to improve safety in patients with sus-
tained ventricular tachycardia, heart failure and sinus
node dysfunction. These data confirm the usefulness of
a clinicalclassification system based on severityof rhythm
disorder and presence of structural heart disease in pre-
dicting serious adverse proarrhythmic events with fle-
cainide.
(1 Am Coil CardioI1986;8:607-1S)
determine whether the arrhythmia is likely to be benign ,
potentially lethal or lethal to the patient (2). Criteria for
such a classification based on clinical experience have been
suggested, including consideration of the degree of struc-
tural heart disease and the hemodynamic consequences of
the ventricular arrhythmia. New potent antiarrhythmic agents
that belong to the modified Vaughn-Williams classification
IC have recently been made available (3). Such agents need
to be assessed to determine their potential to cause proar-
rhythmic or other adverse cardiac event s .
The objective of this study was to evaluate the incidence
of life-threatening or serious adverse cardiac reactions to
the use of the newly available class IC antiarrhythmic agent
flecainide in patients at various degrees of risk: those with
or without structural heart disease . those with arrhythmias
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of different levels of seventy and those treated with high
versus lower initial doses. Such an evaluation may serve as
the basis for developing a clinical approach to the use of
flecainide that will optimize its benefit and minimize
its risk.
Methods
The flecainide data base. The flecainide clinical effi-
cacy and safety data base (St. Paul, Minnesota) collected
from February 1980 to July 1985 was reviewed retrospec-
tively to define the relative risks of death and serious adverse
cardiac experiences in a patient population stratified for
severity of underlying ventricular arrhythmia, presence or
absence of structural heart disease, dose of flecainide ad-
ministered and administration of flecainide as part of out-
patient or inpatient therapy. This data base comprised 1,330
patients derived from the United States data base plus two
European trials, as follows:
I. An early in-hospital dose-ranging study and its long-term
follow-up in 37 patients (4-6).
2. An outpatient double-blirid parallel-designed compara-
tive study of flecainide versus quinidine and its long-
term follow-up in 260 patients (7).
3. A prematurely discontinued attempt at studying flecain-
ide in IO patients in the early postmyocardial infarction
period.
4. A study in 76 patients evaluating the safety and efficacy
of chronic oral flecainide therapy from Rotterdam, The
Netherlands.
5. A compassionate use experience (8) using a 400 mg/day
initial dose with upward titration at investigator discre-
tion and primarily comprising 277 patients with lethal
ventricular arrhythmias. This study will be called the
"high initial dose compassionate study."
6. A study (9) in 429 patients with ventricular tachycardia
treated in-hospital under monitored conditions with a 200
mg/day initial dose and slow upward titration. This study
will be called the "low initial dose ventricular tachy-
cardia study."
7. An open label safety and efficacy study in 86 patients
with various forms of ventricular arrhythmias.
8. A postmarketing surveillance study in 155 patients con-
ducted in the United Kingdom.
Stratification variables. Clinical strata of interest in
assessing risk/benefit ratio were defined before retrospective
data base analysis. Patients from this data base were strat-
ified according to the severity of their underlying ventricular
arrhythmia, classified into 1) those with premature ventric-
ular complexes only, 2) those with nonsustained ventricular
tachycardia, and 3) those with sustained ventricular tachy-
cardia or ventricular fibrillation, or both. Sustained ven-
tricular tachycardia was defined as ventricular tachycardia
lasting 30 seconds or longer, requiring cardioversion or
associated with hemodynamic consequences such as syn-
cope or hypotension. Nonsustained ventricular tachycardia
was defined as three or more consecutive ventricular com-
plexes lasting less than 30 seconds and not associated with
hemodynamic consequences.
The data base was further classified according to the
presence or absence of structural heart disease. Structural
heart disease was considered to be present when a patient
had atherosclerotic coronary artery disease, significant val-
vular heart disease, congenital heart disease, cardio-
myopathy or the presence of a ventricular aneurysm or a
history of previous cardiac surgery, Patients with cardio-
megaly by chest X-ray film, echocardiography or cardiac
catheterization were also considered to have structural heart
disease. Patients categorized by investigators as having pri-
mary electrical heart disease or no apparent cause for the
ventricular arrhythmia were considered to have no structural
heart disease.
Patients were further classified as having received orally
200, 300, 400 or 600 mg/day of fiecainide. Patients who
received a dose of less than 200 mg/day were included in
the 200 mg/day classification. No patient received more than
600 mg/day. Intermediate doses were rounded upward. The
sample size for each total daily dose level was based on the
number of patients who at any time while receiving fle-
cainide were exposed to that total daily dose of the drug.
Patients were counted more than once in the denominator
if they were exposed to multiple doses of flecainide. They
were counted in the numerator at the dose they were re-
ceiving when the adverse event occurred. An adverse event
was attributed only to the dose of flecainide at which it
occurred.
Patients were also categorized into those who received
out-of-hospital or in-hospital initiation offiecainide therapy.
Treatment was initiated outside the hospital in all patients
in the flecainide-quinidine comparison study and its follow-
up. Approximately 25% of patients in the open label safety
and efficacy study and approximately 60% in the postmar-
keting surveillance study conducted in the United Kingdom
began treatment with flecainide as outpatients. All other
patients had inpatient initiation of flecainide.
Adverse cardiac events. The adverse cardiac events
reviewed included occurrence of proarrhythmia, congestive
heart failure and conduction disturbances, Proarrhythmic
events were identified by a direct, retrospective question-
naire from each investigator concerning each patient entered
into the previously cited studies before March 1983, or after
that time (prospectively) by case report forms designed to
specificallydefine proarrhythmic events. Proarrhythmic events
were classified into one of three categories:
1. Those arrhythmic events that resulted in death.
2. Those events that were considered serious but non-
lethal, defined as worsened ventricular arrhythmias that re-
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quired immediate termination with drugs, overdrive pacing
or cardioversion. If the proarrhythmic event was associated
with hypotensive symptoms, it was also considered serious
but nonlethal.
3. Other proarrhythmic events as judged by the inves-
tigator included those with an increase in premature ven-
tricular complexes (using previously published criteria) (8),
new or increased frequency ofnonsustained ventriculartachy-
cardia or new ventricular arrhythmias characterized by a
change in configuration or rate (of ventricular tachycardia)
but which did not result in worsening of symptoms as com-
pared with baseline.
Congestive heart failure resulting in death or discontin-
uation of fiecainide was also reviewed. This information
was obtained from prospective data; investigators were spe-
cifically asked to assess patients for congestive heart failure,
determine whether it was a new development or an exac-
erbation of a prior state and evaluate its impact on the
patient's care.
All patients with documented conduction disturbances
were reviewed. Disturbances considered to be important
were defined as new advanced atrioventricular (AV) block
(greater than first degree) or sinus node dysfunction with
sinus pauses or arrest, junctional escape rhythms or new
symptomatic sinus bradycardia as defined by the individual
investigators.
All deaths in the data base were reviewed and the cause
of death, whether drug-related or not, was categorized into
the following: I) noncardiac death; 2) death due to acute
myocardial infarction documented by typical electrocardio-
gram and enzyme changes or autopsy, or both; 3) death due
to congestive heart failure or low output states; 4) in-hospital
sudden arrhythmic death; and 5) out-of-hospital sudden death.
Role of high versus low dosing schedule. Data from
the 277 patients in the high initial dose compassionate study
and data from the 429 patients in the low initial dose ven-
tricular tachycardia study were displayed separately to de-
fine the effects of a different dosing regimen on the incidence
of various cardiac events. Analysis of patient demographics,
cardiac disease status and arrhythmia diagnoses confirmed
that these two study populations were identical and differed
only in the dosing regimens employed. The initial dose of
flecainide used in the high initial dose compassionate study
was 400 mg/day orally, with a maximum of 600 rug/day;
no specific requirement was made as to dose escalation
intervals, the need for cardiac monitoring or the use of
flecainide plasma levels in guiding therapy. Conversely,
patients enrolled in the low initial dose ventricular tachy-
cardia study were required to be treated initially in the hos-
pital under monitored conditions with the dose regimen start-
ing at 200 mg/day and increasing, only if necessary, to a
maximum of 400 mg/day, in doses of 50 mg twice daily at
intervals no more frequent than every 4 days. Plasma mon-
itoring was used to avoid plasma levels greater than 1.0
jLg/ml. Because of this difference in dose recommendations,
patients in the low initial dose ventricular tachycardia study
tended to receive lower maintenance doses. Half of the
patients in the high initial dose compassionate study received
maintenance doses greater than 300 mg/day, whereas 80%
of the patients in the ventricular tachycardia study were
treated with 300 mg/day or less.
Time of occurrence of adverse events. These events
were separated into those occurring within 14days and those
occurring more than 14 days after initiation of flecainide
therapy. Events occurring within 14 days were of interest,
because hospitalization during initiation of therapy might
reduce the risk to the patient of any serious cardiac events
that occurred. Full dose ranging, beginning at 100 mg every
12 hours with increments every 4 days to 150 and 200 mg
doses may require up to 12 or more days of observation
until the effective dose is achieved. This analysis was in-
tended to identify groups of patients at risk of serious cardiac
events early in therapy, so that appropriate recommenda-
tions could be made concerning who ought to be hospitalized
during therapy initiation. Tentative recommendations were
that patients should be hospitalized if they had a history of
sustained ventricular tachycardia, evidence of symptomatic
congestive heart failure or a history of sinus node dysfunc-
tion.
Data analysis. A logit approach was used to evaluate
adverse cardiac events in terms of potential predictors for
their association with the incidence of adverse cardiac events.
For this analysis, the predictors considered were the pres-
ence or absence of structural heart disease and arrhythmia
type. For the compassionate use and ventricular tachycardia
study data, high or low initial starting dose was also con-
sidered as a potential predictor. The significance of each of
these variables as a predictor of outcome, as well as the
independence of these predictors, was assessed. It is evident
that there may be other potential predictors that are not
evaluated in this analysis. However, because of the relative
infrequent occurrence of some of these adverse cardiac events,
a model to assess numerous predictors was not feasible.
Results
Characteristics of study patients. The 1,330 patients
in this data base have been followed up for a mean of
292 ± 393 days (range 1 to 1,843; median 104). Of these
patients, 573 (43%) are still taking flecainide at a mean
follow-up time of 506 ± 464 days (range 4 to 1,843). Of
the remaining patients, 157 (12%) discontinued therapy be-
cause drug efficacy was inadequate and 145 (11%) died, 77
(9%) because of aggravation of arrhythmia, 19 (1.5%) be-
cause of congestive heart failure, 20 (1.5%) because of
conduction changes and 216 (16%) because of other factors,
such as completion of the study, nonqualification, poor com-
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Table 1. Patients in Data Base Stratified for Various Baseline Characteristics and Doses Received
PVC Only Nonsustained VT Sustained VT Total
Structural heart disease
No 132 (28.1%) 64 (l3 .6%) 28 (7.2%) 224 (16.8%)
Yes 338 (71.9%) 405 (86.4%) 363 (92.8%) 1,106 (83.2%)
Total 470 (100%) 469 ( 100%) 391 (100%) . 1,330 (100 .0%)
Total daily dose (mg)*
200 260 (55.3%) 347 (74.0%) 301 (77.0%) 908 (68.3%)
300 142 (30.2%) 250 (53.3%) 195 (49.9%) 587 (44. 1%)
400 324 (68.9%) 218 (46.5%) 160 (40.9%) 702 (52.8%)
600 44 (9.4%) 50 (10.7%) 25 (6.4 %) 11 9 (8.9%)
Study
High initial dosecompassionate use study 59 (12.6%) 118 (25.2%) 100 (25.6 %) 227 (17.1%)
Low initial dose VT study 27 (5.7 %) 204 (43.5%) 198 (50.6%) 429 (32.3%)
Outpatient initiation of therapy 273 88 15 376
*Patients were included more than once ifexposedto multiple flecainide dosages. PVC = premature ventricular complex; VT = ventricular tachycardia.
pliance, intercurrent illness, personal decision and loss to
follow-up.
Table J details the number of patients in each baseline
subgroup, defined by type of ventricular arrhythmia as it
related to structural heart disease, total daily dose and out-
patient-inpatient initiation of therapy. The patients were ap-
proximately equally grouped into those who were treated
for premature ventricualr complexes alone (n = 470), non-
sustained ventricular tachycardia (n = 469) or sustained
ventricular tachycardia (n = 391). Approximately 80% of
patients had structural heart disease, and approximately 75%
had therapy initiated while they were inpatients. Almost
90% of patients in the data base received 400 mg/day or
less of f1ecainide .
Proarrhythmia. Proarrhythmic events were recorded in
90 (6.8%) of the 1,330 patients in the data base. Table 2
shows that patients with sustained ventricular tachycardia
had a much greater incidence (16.4%) of proarrhythmic
events than did those with premature ventricular complexes
(1.7%) or nonsustained ventricular tachycardia (3.8%). The
patients with sustained ventricular tachycardia in the high
initial dose compassionate study had twice the incidence of
proarrhythmic events (26%) compared with the patients in
the low initial dose study of ventricular tachycardia (13. 1%).
Analyses indicated that type of ventricular arrhythmia (p :5
0.01) and initial f1ecainide dose (p :5 0.05) were both sig-
nificant independent predictors of proarrhythmic events.
Table 2. Summary of All Proarrhythmic Events
Table 3 shows the incidence of possible or probable
proarrhythmia-induced deaths that occurred in 13 patients
(1.0%) in the entire group of 1,330 . This table shows that
no deaths occurred from proarrhythmia in patients treated
for premature ventricular complexes. Only I death (0 .2%)
occurred among the 469 patients treated for nonsustained
ventricular tachycardia. That death occurred in the high
initial dose compassionate study ( I of 11 8 patients), whereas
no deaths have occurred in the 204 patients treated for non-
sustained ventricular tachycardia in the low initial dose ven-
tricular tachycardia study. The patient with nonsustained
ventricular tachycardia who died was an 80 year old man
with severe coronary artery disease, New York Heart As-
sociation class III congestive heart failure and recent sub-
endocardial myocardial infarction with pulmonary edema.
Flecainide was begun at 200 mg/day and increased to 400
mg/day, with good control of ventricular arrhythmia. He
was discharged home 9 days after starting ftecainide and
after 2 days of taking 400 mg/day. He returned to the emer-
gency room on the evening of discharge with a wide irreg-
ular tachycardia without P waves that deteriorated into car-
diogenic shock and death. The relation of f1ecainide (versus
deteriorating ischemic heart disease) to the terminal ar-
rhythmia was not clear.
In patients treated for sustained ventricular tachycardia,
a 10% incidence (10 of 100 patients) of proarrhythmic death
was noted in the high initial dose compassionate study; this
Structural heart disease
No
Yes
Total
Study
High initial dose compassionate use study
Lowinitial doseVT study
Abbreviations as in Table I.
PVC Only
41132 (3.0%)
4/338 ( 1.2%)
8/470 (1.7%)
0/59 (0.0%)
2/27 (7.4%)
Nonsustained VT
2/64 (3.1%)
16/405 (4 .0% )
18/469 (3.8%)
2/118 (1.7%)
6/204 (2.9%)
Sustained VT
2/28 (7.1%)
62/363 ( 17. 1% )
64/391 (16.4%)
26/100 (26.0%)
26/198 (13.1%)
Total
8/224 (3.6%)
82 / 1, 106 (7.4%)
90/1,330 (6.8%)
281277 (10.1%)
34/429 (7.9%)
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Structural heart disease
No
Yes
Total
Study
High initial dose compassionate use study
Low initial dose VT study
Abbreviations as in Table I.
01132 (0.0%)
01338 (0.0%)
0/470 (0.0%)
0/59 (0.0%)
0127 (0.0%)
0/64 (0.0%)
1/405 (0.2%)
1/469 (0.2%)
1/118 (0.8%)
0/204 (0.0%)
0/28 (0.0%)
12/363 (3.3%)
12/391 (3.1%)
10/100 (10.0%)
11198 (0.5%)
0/224 (0.0%)
1311,106 (1.2%)
1311,330 (1.0%)
11/277 (4.0%)
1/429 (0.2%)
rate dropped to 0.5% (1 of 198 patients) in the low initial
dose ventricular tachycardia study, a 20-fold decrease (p <
0.01). In fact, no patient in the latter study died of a proar-
rhythmic event in the subsequent 2 1/2 years before this
data analysis. In the compassionate use and ventricular
tachycardia studies, the type of arrhythmia (p < 0.05) and
initial dose (p < 0.01) were found to be independent pre-
dictors for proarrhythmic death.
Table 4 shows the incidence of serious nonlethal proar-
rhythmic events. These occurred in 30 patients (2.3%), 29
of whom had structural heart disease. None of the patients
treated for premature ventricular complexes developed a
serious nonlethal proarrhythmic event. Of the four patients
with nonsustained ventricular tachycardia who had a serious
nonlethal proarrhythmic event, all had structural heart dis-
ease, three had congestive heart failure and two had de-
pressed left ventricular ejection fraction (29 and 36%, re-
spectively). In three of the patients, the proarrhythmic event
resulted in syncope, and in the other resulted in a wide
complex tachycardia that required cardioversion. Patients
with sustained ventricular tachycardia had the highest in-
cidence of serious nonlethal proarrhythmic events (6.6%).
Table 5 details other proarrhythmic events. The inci-
dence of this form of proarrhythmia did not appear to be
related to the presence or absence of structural heart disease
but did correlate with the severity of the baseline arrhythmia.
Patients with sustained ventricular tachycardia had the high-
est risk for this type of proarrhythmia.
Table 6 shows the relation offiecainide dose to types of
proarrhythmic events that occurred in patients with sus-
tained ventricular tachycardia. There was no consistent re-
Table 4. Serious Nonlethal Proarrhythmic Events
lation between dose and the incidence of proarrhythmic
events of any type in patients treated for premature ven-
tricular complexes only or for nonsustained ventricular
tachycardia. These data demonstrate that there is a dose
relation to all proarrhythmic events, to those resulting in
death and to those of the serious nonlethal type in patients
with sustained ventricular tachycardia receiving 200 to 400
mg/day of flecainide. The number of patients exposed to
600 mg/day is too small to draw meaningful conclusions
about a relation.
Congestive heart failure. Of 1,330 patients, 6 (0.5%)
died from congestive heart failure that might be attributed
to flecainide and 19 had flecainide therapy discontinued after
developing new or worsening congestive heart failure. All
six patients who died had significant myocardial dysfunction
before receiving flecainide. There was no relation between
congestive heart failure and the dose of flecainide received.
Four of the patients who died had a history of sustained and
two had history of nonsustained ventricular tachycardia. Of
the two patients with nonsustained ventricular tachycardia,
one had a history of myocardial infarction with recent ex-
acerbation of angina and an exacerbation of congestive heart
failure 3 weeks before receiving flecainide. After receiving
flecainide for 3 days, he developed increasingly severe
congestive heart failure and died. The investigator believed
that the sudden onset may have been caused by new ischemia
and therefore a definite relation with flecainide could not be
established. The second patient who had nonsustained ven-
tricular tachycardia had coronary artery disease and an ejec-
tion fraction of 22%. He had done well with flecainide
therapy for 3 months when signs of worsened congestive
Structural heart disease
No
Yes
Total
Study
High initial dose compassionate use study
Low initial dose VT study
Abbreviations as in Table I.
PVC Only
01132 (0.0%)
01338 (0.0%)
0/470 (0.0%)
0/59 (0.0%)
0127 (0.0%)
Nonsustained VT
0/64 (0.0%)
4/405 (1.0%)
4/469 (0.9%)
01118 (0.0%)
2/204 (1.0%)
Sustained VT
1/28 (3.6%)
25/363 (6.9%)
26/391 (6.6%)
8/100 (8.0%)
12/198 (6.1%)
Total
1/224 (0.4%)
2911,106 (2.6%)
30/1,330 (2.3%)
8/277 (2.9%)
14/429 (3.3%)
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Table S. Other Proarrhythmic Events
PVC Only Nonsustained VT Sustained VT Total
Structural heart disease
No 41132 (3.0%) 2/64 (3, 1%) 1128 (3,6%) 7/224 (3,1%)
Yes 4/338 (1.2%) 11 /405 (2,7%) 25/363 (6.9%) 40/ 1.106 (3.6%)
Total 8/470 (1,7%) 13/469 (2,8%) 26/391 (6.6%) 4711 ,330 (3.5%)
Study
High initial dose compassionate 0/59 (0,0%) 1111 8 (0,8 %) 811 00 (8,0%) 9/277 (3,2%)
use study
Low initial dose VT study 2/27 (7.4%) 4/204 (2,0%) 13/ 198 (6,6%) 19/429 (4.4%)
Abbreviations as in Table I ,
heart failure developed. Despite a decre asing dosage of f1e-
cainide, he was admitted for uncompensated congestive heart
failure 9 days later and died I week afterward of ventricular
tachycardia, considered to be seco ndary to worsened
congestive heart failure, The investigator stated that the
death was probably not related to f1ecainide.
New or worsened congestive heart fa ilure caused dis-
continuation ofjiecainide in / 9 patients (1.4%). All 19 had
struc tural heart disease and there was no relation between
discont inuation for congestive heart fai lure and the type of
underl ying arrhythmia or dose of f1 ecainide. Of the 19 pa-
tient s, 3 (0 .6%) of 470 were treated for premature ventric-
ular complexes only, 10 (2 . 1%) of 469 for nonsu stained
ventricular tachycardia and 6 ( 1.5%) of 39 1 for sustained
ventricular tachycardia . Ten (53%) of the 19 patients dis-
continued f1ecainide within 14 days of initiation of the dose .
Two of these 10 had sustained ventricular tachycard ia. and
6 had severe congestive heart failure with low ejection frac-
tion ; therefore , 8 of the 10 patients who had to discontinue
therapy within 14 days would have received in-hospital ini-
tiation of flecainide. The other two patient s who would not
have received in-hospital initiation were treated for non-
sustained ventricular tachycardia and developed symptoms
of conges tive heart failure as outp atient s 7 and II days,
respect ively , after initiation of f1 ecainide. Both responded
to discontinuation of f1ecainide without requ iring speci fic
therapy for congestive heart failure .
Conduction disturbances. Significant conduction dis-
turbances were reported in 29 (2 .2%) of the 1,330 patients
and none were fatal. The incid ence of significant conduction
disturbances was not related to the severity of the underlying
arrhythmia , presence or absence of structural heart disease
or dose of f1ecainide. Of these 29 patients, II developed
symptoms associated with the conduction disturbances (diz-
ziness , weakness or presyncope in 7 and syncope in 4) .
Table 7 details the symptomatic conduction disturbances by
subgroups, and shows that the prevalence of these distur-
bances was not related to the type of ventricular arrh ythmi a
treated or the total daily dose of drug.
Of the 29 patients who developed conduction distur-
bances. 20 discontinued f1ec ainide and 9 continued taking
the drug , 8 of whom received a permanent pacemaker. Be-
fore initiati on of f1ecainide therapy, 19 of the 29 pat ient s
had known preexisting conduction disturbances . Of the four
patient s who developed syncope , two had known underl ying
sinus bradycardia due to sick sinus syndrome and the other
two had sustained ventricular tachycardia and left bundl e
branch block at basel ine. In all four case s the syncope that
occurred when the patient was given f1ec ainide was due to
prolonged sinus pauses. No patient developed syncope be-
cause of the occurrence of AV node or His-Purkinje system
complete heart block.
Deaths. Of the 1,330 pat ient s rece iving f1ecainide, 123
(9 .7%) died . Both the presence of structural heart disease
(p :5 0 .0 I) and the type of ventricular arrhythmia (p :5 0.05)
were found to be independent predi ctors of the incidence
of death . The incidence of death in patient s with sustained
ventricular tachycardia ( 16 . 1%) was greater than that for
patients with premature ventricular complexes (3. 2%) or
nonsustained ventricular tachycardia (9 .6%). All but three
of these deaths occurred in patients with structural heart
disease. Of the three patient s without structural heart dis-
Table 6. Relation of Flecainide Dose to Type of Proarrhythmic Events in Patients Treated for
Sustained Ventricular Tachycardia
All Serious Nonlethal Deaths
To tal daily dose (mg)*
200 14/301 (4.7%) 7/301 (2.3%) 0/301 (0.0%)
300 22/195 (11.3%) 9/195 (4.6%) 3/ 195 ( 1.5%)
400 24/160 (15.0%) 711 60 (4.4%) 8/160 (5.0%)
600 4/25 (16.0%) 3/25 (12.0%) 1/25 (0.5%)
"Patients were included more than once if exposed to multiple flecainide dosages .
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Table 7. Symptomatic Conduction Disturbances
PVC Only Nonsustained VT Sustained VT Total
Structural heart disease
No 3/132 (2.3%) 0/64 (0.0%) 0/28 (0.0%) 31224 (1.3%)
Yes 2/338 (0.6%) 2/405 (0.5%) 4/363 (1.1 %) 8/1,106 (0.7%)
Total 5/470(1.1%) 2/469 (0.4%) 4/391 (1.0%) 11/1,330 (0.8%)
Study
High initial dose compassionate 0/59 (0.0%) 1/118 (0.8%) 4/100 (4.0%) 5/277 (1.8%)
use study
Low initial dose VT study 0127 (0.0%) 1/204 (0.5%) 0/198 (0.0%) 1/429 (0.2%)
Abbreviations as in Table I.
ease, one died of metastatic carcinoma, one had unobserved
sudden death at home after 7 months of flecainide therapy
in which the cause of death was possible cerebral vascular
accident secondary to hypertensive disease and the third
patient had sudden cardiac death at home 16 days after
initiation of flecainide but had a prior history of resuscitation
from sudden cardiac death. All three of these patients had
documented control of their ventricular arrhythmia while
taking flecainide before death.
In-hospital arrhythmic death occurred in 42 patients (3.2%)
and out-of-hospital sudden death in 49 patients (3.7%), which
includes those deaths thought to be due to proarrhythmic
events, as discussed earlier. All but two of these deaths
occurred in patients with structural heart disease (p < 0.05)
and there was a highly significant (p < 0.05) independent
relation to the type of underlying ventricular arrhythmia
(Table 8). There was no clear overall relation between dose
of flecainide and sudden death, but there was a tendency
for higher doses to be associated with sudden death in pa-
tients with sustained ventricular tachycardia. Patients treated
in the high initial dose compassionate study had twice the
mortality rate compared with those treated in the low initial
dose ventricular tachycardia study.
Events within 14 days of initiation of therapy. The
occurrence of adverse cardiac events and death was corre-
lated with whether flecainide was initiated as inpatient or
outpatient therapy, and how long after initiation these events
occurred. No proarrhythmic death occurred when flecainide
therapy was initiated in outpatients with premature ventric-
ular complexes or nonsustained ventricular tachycardia. Fif-
teen patients in this database were exposed to flecainide as
outpatients with the diagnosis of sustained ventricular tachy-
cardia, and one (6.7%) had a proarrhythmic death.
Twelve of the 13 proarrhythmic deaths occurred within
14 days of initiation of jlecainide, II in patients with sus-
tained ventricular tachycardia and I in a patient with a
nonsustained ventricular tachycardia plus class III conges-
tive heart failure with an ejection fraction of less than 30%.
All 12 patients would have been hospitalized if the rec-
ommendations for hospitalization had been followed (that
is, hospitalize patients with sustained ventricular tachycar-
dia, evidence of symptomatic congestive heart failure or
history of sinus node dysfunction).
Among the 30 patients with a serious nonlethal proar-
rhythmic event, 23 events (77%) occurred within 14 days
after initiation of flecainide therapy. All but one of these
patients would have received in-hospital initiation of fle-
cainide if recommended guidelines for such initiation had
been used.
Three of the six deaths due to congestive heart failure
occurred within 14 days of initiation of flecainide. All three
would have had in-hospital initiation of treatment using the
recommended criteria for inpatient initiation.
Ofthe four patients who developed syncope onjlecainide,
three experienced the event within 14 days of initiation of
flecainide. One had been treated for sustained ventricular
tachycardia and the other two had known sinus node dys-
function at baseline. All three, therefore, would have had
Table 8. In-Hospital Arrhythmic Deaths and Out-of-Hospital Sudden Deaths
PVC Only Nonsustained VT Sustained VT Total
Structural heart disease
No 1/132 (0.8%) 0/64 (0.0%) 1/28 (3.6%) 2/224 (0.9%)
Yes 10/338 (3.0%) 30/405 (7.4%) 49/363 (13.5%) 89/1,106 (8.0%)
Total 11/470 (2.3%) 30/469 (6.4%) 50/391 (12.8%) 91/1,330 (6.8%)
Study
High initial dose compassionate 4/59 (6.8%) 7/118 (5.9%) 20/100 (20.0%) 31/277 (11.2%)
use study
Low initial dose VT study 0127 (0.0%) 9/204 (4.4%) 18/198 (9.1%) 27/429 (6.3%)
Abbreviations as in Table I.
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in-hospital initiation of flecainide based on the recommen-
dation that patients with sinus node dysfunction or sustained
ventricular tachycardia be initially treated as inpatients.
Thirty-seven patients with in- or out-of-hospital sudden
death died within 14 days of initiation offlecainide therapy.
Twenty-seven of these 37 patients were treated for sustained
ventricular tachycardia and the other 10 had evidence of
significant myocardial dysfunction. Therefore, all of these
patients would have received in-hospital initiation of fle-
cainide based on the recommendation for inpatient
treatment.
Discussion
The data in this study were derived from a carefully
recorded, prospectively determined set of trials of the new
potent class IC antiarrhythmic agent flecainide acetate. This
large data base can therefore serve as a means of defining
relations among the classification of ventricular arrhythmias,
dose rate of flecainide administration and the occurrence of
serious adverse cardiac events.
Classification of arrhythmia versus efficacy and ad-
verse events. Classification of patients with ventricular ar-
rhythmias into those with 1) premature ventricular com-
plexes only, 2) nonsustained ventricular tachycardia, and
3) sustained ventricular tachycardia has previously been
demonstrated to provide useful correlations with the efficacy
of flecainide (4-9). Among patients with premature ven-
tricular complexes only and nonsustained ventricular tachy-
cardia who were treated in placebo-controlled and quinidine
comparative randomized trials (4-7), 80 to 90% of patients
demonstrated excellent efficacy with flecainide. Conversely,
among patients treated for sustained ventricular tachycardia
using noninvasive or electrophysiologic approaches, or both,
approximately 20 to 50% of patients responded to flecainide
(9-11). This is a higher response rate than that seen with
other class I antiarrhythmic agents (l,2).
This study defines the relative risk of serious adverse
cardiac effects: proarrhythmia, congestive heart failure and
conduction disturbances with flecainide therapy; it also shows
that their incidence is correlated closely with the classifi-
cation system used for ventricular arrhythmias (2,3). How-
ever, the development of symptomatic conduction distur-
bances is related to the e1ectrophysiologic action of flecainide
and is better predicted by the baseline sinus node function
rather than by the class of ventricular arrhythmia before
treatment.
Of the 470 patients treated for premature ventricular com-
plexes only, there were no flecainide-related deaths, no se-
rious proarrhythmic events and a low sudden cardiac death
rate (2.3%). Among the 469 patients treated for nonsus-
tained ventricular tachycardia, there was one possible proar-
rhythmic death, four serious nonlethal proarrhythmic events,
two deaths due to congestive heart failure and a combined
sudden death incidence in these patients of 6.4%.
Outpatient versus inpatient initiation of ftecainide
therapy. The data herein support the view that flecainide
can be safely initiated in selected outpatients because the
prevalence of serious adverse cardiac reactions is quite low.
Obviously, more data are required to confirm these results
with a higher level of confidence. Hospitalization is rec-
ommended for all patients with a history of sustained ven-
tricular tachycardia when treated with any antiarrhythmic
agent. For patients with less severe arrhythmias, hospital-
ization during initiation of flecainide therapy is recom-
mended if they have symptomatic congestive heart failure
or sinus node dysfunction. These characteristics were pres-
ent in all but three of the patients treated for premature
ventricular complexes or nonsustained ventricular tachy-
cardia who died or had serious adverse cardiac experiences
within 14 days of therapy. All 10 patients treated for pre-
mature ventricular complexes or nonsustained ventricular
tachycardia who had in- or out-of-hospital sudden death
within 14 days would have received in-hospital initiation
of flecainide. Three of the four patients with serious
proarrhythmic events would have been hospitalized. The
remaining patient who was treated for nonsustained ven-
tricular tachycardia reported to the emergency room with
light-headedness and was found to have a wide complex
tachycardia requiring cardioversion. Eight of the 10 patients
treated for premature ventricular complexes or nonsustained
ventricular tachycardia who required early discontinuation
of flecainide because of congestive heart failure also would
have been hospitalized. The two who would not have been
hospitalized had only mild symptoms of congestive heart
failure and required no therapy other than discontinuation
of flecainide. Thus it is clear that all patients who might
have benefited from hospitalization would be hospitalized
if the present recommendations were followed.
Risk versus benefit of ftecainide. Thus, the concern of
benefit versus risk for the use of flecainide in patients with
ventricular arrhythmias can be more clearly estimated by
the data provided in this report. Although it is quite clear
that patients benefit by elimination of hemodynamic or life-
style-limiting symptoms when the severity of arrhythmia is
reduced by the potent agent flecainide, it is still unknown
whether sudden cardiac death in high risk patients is in fact
prevented when antiarrhythmic agents are used to eliminate
the major risk factor of ventricular arrhythmias. Very few
data exist that analyze the serious adverse cardiac reactions
using other antiarrhythmic drugs in relation to the nature of
the patients being treated and the characteristics of their
ventricular arrhythmias. We do know, for example, that
initiating quinidine therapy in outpatients with benign or
potentially lethal ventricular arrhythmias similarly has a very
low incidence of proarrhythmia (about 6%) and no deaths,
as was also seen in this study using flecainide (12). A much
higher prevalence of proarrhythmia, and particularly the
presence of torsade de pointes, is mostly seen in patients
lACC Vol. 8, No.3
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treated with quinidine who manifest atrial fibrillation,
congestive heart failure or hypokalemia.
Thus, it appears that it is more important to understand
the clinical conditions associated with the arrhythmia rather
than the arrhythmia itself if one wishes to predict the po-
tential for serious adverse cardiac reaction due to antiar-
rhythmic drug therapy. We therefore recommend for fle-
cainide, as for other antiarrhythmic agents, in-hospital
initiation of therapy for patients with sustained ventricular
tachycardia, serious compromised left ventricular function
(particularly with symptomatic congestive heart failure) and
unstable cardiac states, such as unstable ischemia and elec-
trolyte imbalance (particularly hypokalemia). Patients with
sick sinus syndrome are at risk of developing higher degrees
of block from potent antiarrhythmic drugs such as flecainide,
and therefore in all such patients such therapy should be
initiated in the hospital.
Clinical use of f1ecainide in serious cases. The data
comparing the high initial dose compassionate study and
the low initial dose ventricular tachycardia study demon-
strate clearly the principle that the seriously ill patient with
sustained ventricular tachycardia must be treated not only
in the hospital, but also with a careful dosage regimen,
starting with a small total daily dose of the drug and not
increasing that dose until steady state has been reached.
Initiating therapy with a lower dose of flecainide at 100 mg
twice a day is a safety precaution that should be followed
for all patients to be treated because this agent is so potent
and higher doses are often not needed. Thus, a regimen for
flecainide using an initial dose of 100 mg twice a day with
incremental increases of 50 mg twice a day every 4 days
under careful monitoring of both the electrocardiogram and
blood levels has markedly reduced the prevalence of serious
proarrhythmia, congestive heart failure and death. Patients
rarely require more than 200 mg twice a day when lethal
ventricular arrhythmias are present, whereas up to 600 mg/day
of flecainide has been found to slightly increase the rate of
successful treatment in patients with benign or potentially
lethal ventricular arrhythmias whose treatment is initiated
outside the hospital (4-7).
Conclusions. It is not only the form of the ventricular
arrhythmia, but also the accompanying clinical character-
istics, that determine the predictability of serious adverse
cardiac reactions to antiarrhythmic drugs. The classification
of patients with ventricular arrhythmias into those with pre-
mature ventricular complexes, nonsustained ventricular
tachycardia and sustained ventricular tachycardia can be
used not only to predict the efficacy rates of flecainide and
other antiarrhythmic agents, but also the ability to predict
serious adverse cardiac events. The use of this classification
system to report antiarrhythmic drug trial efficacy and safety
results and to define patients for sudden cardiac death pre-
vention trials seems warranted.
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